Keymed Biosciences Co.ltd

This study tests a new drug called CM336 in people with autoimmune cytopenia, a condition where the immune system attacks blood cells. The drug aims to control the disease by targeting certain immune cells. About 158 adults with relapsed or refractory forms of immune thrombocytop…

This study tests an experimental injection called CM512 for people with chronic spontaneous urticaria (CSU) — long-lasting hives with itching and welts that don't go away with regular allergy pills. About 48 adults will receive either CM512 or a placebo to see if the drug reduces…

This study tests an experimental drug called CM336 in adults whose primary light-chain amyloidosis has come back or not responded to prior treatment. The drug is a bispecific antibody designed to help the immune system attack the abnormal cells causing the disease. The main goal …

This study tests a new drug called CM518D1 in about 434 adults with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. Participants will receive the drug and be closely mon…

This study looks at the long-term safety and effectiveness of a drug called CM512 for people with atopic dermatitis (eczema). It is for patients who already finished a previous CM512 study. The main goal is to track any side effects over time. About 246 adults will take part.

This early-stage study tests a new drug, CM383, in 30 healthy men to see how the body absorbs and processes it, and to check for any side effects. Participants receive a single dose either through an IV or an injection. This study does not aim to treat any disease.

This early-stage study tests a new drug called CM559 in healthy adult men to see if it is safe and how the body handles it. About 40 participants will receive a single dose of CM559 or a placebo. The study focuses on side effects and how the drug moves through the body, not on tr…